Double Point Ventures

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

GEMMABio is a therapeutics company dedicated to developing gene therapies for individuals with rare diseases. Its mission is to accelerate research and enhance global access to these life-changing treatments, aiming to bring gene therapy discoveries from the lab to patients worldwide more swiftly and affordably.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on developing and commercializing therapeutics for severe, rare, and genetic diseases. The company's lead product, LUM-201, is an oral small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. In addition to its primary focus, Lumos has a licensing agreement with Ellipses Pharma Limited for the development and commercialization of nanoparticle formulations aimed at oncology indications. Founded in 2011, Lumos Pharma also has a commitment to addressing Creatine Transporter Deficiency, leveraging exclusive licenses for technologies developed at the University of Cincinnati and collaborating with key opinion leaders and the National Institutes of Health. The company engages in both clinical and preclinical research, exploring treatments that may enhance immune responses against cancer, and has partnerships for manufacturing its therapeutics.

ImmunOs Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel human immunomodulatory proteins and therapies for cancer and autoimmune diseases. The company aims to enhance cancer treatment by leveraging proteins with direct anti-tumor effects that remodel the tumor microenvironment and by developing antibodies that block activation of specific HLA molecules implicated in autoimmune conditions. Founded in 2014 and based in Schlieren, Switzerland, ImmunOs Therapeutics pursues next-generation therapeutics intended to improve outcomes for patients with serious diseases.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Founded in 2017, DermBiont is a biotechnology company based in Boston, Massachusetts. It specializes in developing skin microbiome therapeutics to treat and prevent various skin diseases, with a focus on fungal infections.